These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37437408)

  • 1. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures:A real-world experience in eastern China.
    Xu S; Xu ZY; Zheng Y; Miao P; Feng J; Guo Y
    Seizure; 2023 Aug; 110():231-237. PubMed ID: 37437408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience.
    Chinvarun Y
    Epilepsia Open; 2022 Mar; 7(1):67-74. PubMed ID: 34741590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry.
    Toledano Delgado R; García-Morales I; Parejo-Carbonell B; Jiménez-Huete A; Herrera-Ramirez D; González-Hernández A; Ayuga Loro F; Santamarina E; Toledo M; Ojeda J; Poza JJ; Molins A; Giner P; Estévez María JC; Castro-Vilanova MD; Zurita J; Saiz-Diaz RA; Gómez-Ibañez A; Rodriguez-Uranga J; Gil-Nagel A; Campos D; Sánchez-Larsen Á; Aguilar-Amat Prior MJ; Mauri Llerda JA; Huertas González N; García-Barragán N
    Epilepsia; 2020 Jun; 61(6):1109-1119. PubMed ID: 32511754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
    Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
    Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study.
    Ma H; Zhu H; Chen F; Yang Y; Qu X; Xu H; Yang L; Zhang R
    Epilepsia Open; 2023 Dec; 8(4):1474-1483. PubMed ID: 37661647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.
    Wang Q; Xu Y; Chen Y; Wu X; Ge Y; Zhu G
    Epilepsy Behav; 2022 Nov; 136():108937. PubMed ID: 36215830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
    Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
    Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study.
    D'Souza W; Alsaadi T; Montoya J; Carreño M; Di Bonaventura C; Mohanraj R; Yamamoto T; McMurray R; Shastri O; Villanueva V;
    Seizure; 2022 Aug; 100():56-66. PubMed ID: 35777333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.
    Rodríguez-Osorio X; Lema-Facal T; Rubio-Nazábal E; Castro-Vilanova MD; Pato-Pato A; Abella-Corral J; Corredera E; López-Ferreiro A; Puy-Núñez A; López-González FJ
    Epilepsy Res; 2021 May; 172():106570. PubMed ID: 33621770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice.
    Trinka E; Alsaadi T; Goji H; Maehara T; Takahashi S; Jacobs J; Renna R; Gil-López FJ; McMurray R; Sáinz-Fuertes R; Villanueva V
    Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of perampanel monotherapy after adjunctive therapy through retention rate in subjects with focal-onset seizures with or without focal to bilateral tonic-clonic seizures: A multicenter retrospective study in Korea.
    Lim SC; Lee WG; Kim DW; Kim KK; Shon YM; Park J; Lee Y; Seo DW
    Epilepsy Behav; 2023 Aug; 145():109291. PubMed ID: 37336136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM).
    Husni RE; Ngo LY; Senokuchi H; Patten A; Hiramatsu H; Watanabe K; Yamamoto T
    Epilepsia Open; 2022 Mar; 7(1):59-66. PubMed ID: 34657389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
    Villanueva V; D'Souza W; Goji H; Kim DW; Liguori C; McMurray R; Najm I; Santamarina E; Steinhoff BJ; Vlasov P; Wu T; Trinka E;
    J Neurol; 2022 Apr; 269(4):1957-1977. PubMed ID: 34427754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.